• Axel Petzold, Edward J Thompson, Geoffrey Keir, Niall Quinn, Bjorn Holmberg, Nil Dizdar, Gregor K Wenning, Olivier Rascol, Eduardo Tolosa, and Lars Rosengren.
• Department of Neuroimmunology, UCL Institute of Neurology, Queen Square, London, UK. a.petzold@ion.ucl.ac.uk
• J. Neurol. Sci. 2009 Apr 15;279(1-2):76-9.

BackgroundTwo cerebrospinal fluid (CSF) biomarkers specific for neurodegeneration have recently emerged - the neurofilament light (NfL, 68 kDa) and heavy (NfH, 190-210 kDa) chains. This study investigated whether the CSF NfH and NfL levels or their stoichiometric relationship changed over time in a neuroprotective treatment trial.MethodsSerial CSF samples (n=95) from 42 patients with multiple system atrophy (MSA), half randomized to treatment with recombinant human growth hormone (r-hGH) and the other half to placebo, were collected at baseline, 6 and 12 months. The concentration of CSF NfL and NfH was determined using standard ELISAs.ResultsThere was no consistent change in the levels of either protein over the 12 month period, or between treatment with active r-hGH versus placebo. The molar stoichiometry of CSF NfL:NfH was 4:1 (R=0.37, p=0.0002) and increased following treatment with r-hGH (p=0.03).ConclusionThese results indicate that CSF levels of both NfL and NfH on their own are not useful markers of disease progression in MSA, at least over a 12-month period. Future work is needed to elucidate whether the CSF stoichiometry and dynamics of Nf subunits in individual patients are a feature of the underlying pathology and of diagnostic or prognostic value.

25 keywords...

hide…